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Abstract Alzheimer’s disease (AD) is an age-related neu-
rodegenerative disease marked by a progressive cognitive
decline. Metabolic impairments are common hallmarks of
AD, and amyloid-b (Ab) peptide and hyperphosphorylated
tau protein—the two foremost histopathological signs of
AD—have been implicated in mitochondrial dysfunction.
Neurosteroids have recently shown promise in alleviating
cognitive and neuronal sequelae of AD. The present study
evaluates the impact of neurosteroids belonging to the sex
hormone family (progesterone, estradiol, estrone, testos-
terone, 3a-androstanediol) on mitochondrial dysfunction in
cellular models of AD: human neuroblastoma cells (SH-
SY5Y) stably transfected with constructs encoding (1) the
human amyloid precursor protein (APP) resulting in overex-
pression of APP and Ab, (2) wild-type tau (wtTau), and (3)
mutant tau (P301L), that induces abnormal tau hyperphos-
phorylation. We show that while APP and P301L cells both
display a drop in ATP levels, they present distinct mito-
chondrial impairments with regard to their bioenergetic
profiles. The P301L cells presented a decreased maximal
respiration and spare respiratory capacity, while APP cells
exhibited, in addition, a decrease in basal respiration, ATP
turnover, and glycolytic reserve. All neurosteroids showed
beneficial effects on ATP production and mitochondrial
membrane potential in APP/Ab overexpressing cells while
only progesterone and estradiol increased ATP levels in
mutant tau cells. Of note, testosterone was more efficient in
alleviating Ab-induced mitochondrial deficits, while proges-
terone and estrogen were the most effective neurosteroids in
our model of AD-related tauopathy. Our findings lend further
support to the neuroprotective effects of neurosteroids in AD
and may open new avenues for the development of gender-
specific therapeutic approaches in AD.
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OXPHOS Oxidative phosphorylation
P Progesterone
P301L Tau mutation
PD Parkinson’s disease
ROS Reactive oxygen species
T Testosterone
wtTau Wild-type tau
Introduction
Alzheimer’s disease (AD) is an age-related neurodegener-
ative disease that accounts for more than 60 % of all
dementia cases. AD will become increasingly burdensome
and costly in the coming years as its prevalence is expected
to double within the next two decades [1]. The disease is
characterized by cognitive deficits and memory loss and,
from a histopathological point of view, by the presence of
amyloid-b (Ab) plaques and neurofibrillary tangles (NFTs)
composed of abnormally hyperphosphorylated tau protein
in the brain. Genetic studies link mutations in the amyloid-
b protein precursor (APP) to familial AD (FAD) cases.
These mutations lead to an increased Ab production in the
brain of AD patients [2]. Interestingly, no mutations in the
tau encoding gene have been identified so far in FAD.
However, such mutations were detected in familial fron-
totemporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17) leading to NFT formation [3].
Both histopathological hallmarks of AD, Ab, and abnormal
tau protein induce synaptic disintegration and oxidative
stress, and disrupt Ca2? homeostasis leading to neurode-
generation [4–6]. Even if FAD cases only represent a small
percentage of all AD patients (less than 1 %), the vast
majority of non-familial AD, termed sporadic AD (SAD),
and FAD patients have a number of disease features in
common, especially the presence of mitochondrial deficits
already at an early AD stage [7–10].
Indeed, mitochondria are essential components of
metabolic function and serve as the ‘‘powerhouses’’ of
cells, providing energy in the form of adenosine triphos-
phate (ATP) that is used by cells to power a variety of
cellular processes including apoptosis, intracellular cal-
cium homeostasis, alteration of the cellular reduction–
oxidation (redox) state, and synaptic plasticity [11, 12].
Mounting evidence suggests that mitochondrial dysfunc-
tion serves as a catalyst in AD, since the disease is
associated with a decline in bioenergetic activity and an
increase in oxidative stress that can already be detected at
early disease stage in both FAD and SAD [10, 13–15].
Indeed, brain glucose hypometabolism has been observed
in AD patients well before the onset of clinical symptoms
[16]. This disease characteristic was also observed in AD
mouse models, bearing mutations in APP and/or tau pro-
tein, in which mitochondrial dysfunction is already obvious
before the appearance of Ab deposits, NFT formation, and
cognitive impairments (reviewed in [10]). With regard to
their critical role in the early pathogenesis of both SAD and
FAD, mitochondria therefore represent an interesting target
for the development of novel treatment avenues.
Based on recent discoveries, interventions that target
mitochondrial deficits, such as the use of neurosteroids,
may serve as potential strategies for the treatment of AD
[17–19]. In 1981, Baulieu and colleagues characterized a
new category of steroids that is synthesized in the nervous
system and persists in substantial amounts after removal of
the peripheral steroidogenic glands [20]. This category of
molecules was dubbed ‘‘neurosteroids.’’ In a recent study,
we characterized the bioenergetic modulating profile of
seven structurally diverse neurosteroids that are known to
be involved in the regulation of brain functions [21–25],
namely progesterone, estradiol, estrone, testosterone, 3a-
androstanediol, DHEA, and allopregnanolone. We had
found that most of the steroids tested by us improved the
bioenergetic activity in neuronal cells by increasing ATP
levels, the mitochondrial membrane potential (MMP), and
mitochondrial respiration, in a similar pattern in SH-SY5Y
neuroblastoma cells as well as in primary neuronal culture
[19]. Our results provided new insights in re-defining the
biological model of how neurosteroids control neuronal
functions, further emphasizing the role of neurosteroids in
neuroprotection.
In line with that study, a growing body of evidence
attests to the neuroprotective effects of neurosteroids,
especially estrogenic compounds, against AD-related cel-
lular injury (reviewed in [18]). However, little is known
about the influence of neurosteroids on AD-related mito-
chondrial dysfunction. Additionally, the primary focus of
neurosteroid treatment in AD has centered in the past on
Ab plaques rather than tau-related NFTs.
Thus, the aim of the current study was to assess whether
neurosteroids of the sex hormone family can attenuate the
toxic effects of Ab and/or abnormal tau on mitochondria
and whether the influence of neurosteroids on tau-related
deficits independent of Ab can be differentiated. For this
purpose, we investigated the effects of progesterone,
estradiol, estrone, testosterone, and 3a-androstanediol on
bioenergetics in SH-SY5Y neuroblastoma cells stably
transfected with wild-type human APP (APP cells) or the
empty vector (Mock cells), and wild-type human tau
(wtTau cells) or mutated tau (P301L cells), respectively. Of
note, both AD cell culture models, APP and P301L cells,
express a variety of neuronal receptors, including steroid
receptors (progesterone, estrogen, and androgen receptors)
and exhibit the characteristics of a mitochondrial mal-
function when compared to their respective controls [26–
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29]. They shared decreased ATP levels as well as impaired
mitochondrial respiration [26, 27] but differed in the
underlying mechanisms. Thus, APP cells presented a defect
in complex IV activity [26], whereas complex I activity
was impacted by mutant tau in P301L cells [27]. On the
basis of our previous findings, it was therefore of interest to
examine whether neurosteroids are able to alleviate mito-
chondrial deficits manifested in these AD cellular models.
In particular, their impact on ATP production, mitochon-
drial membrane potential (MMP), mitochondrial
respiration, and glycolysis was investigated.
Materials and methods
Chemicals and reagents
Dulbecco’s-modified Eagle medium (DMEM), fetal calf
serum (FCS), penicillin/streptomycin, progesterone, 17b-
estradiol, estrone, 3a-androstanediol, pyruvate, hydrogen
peroxide (H2O2), retinoic acid, and brain-derived neu-
rotrophic factor (BDNF) were from Sigma-Aldrich (St.
Louis, MO, USA). Glutamax, B27 supplement, and neu-
robasal medium were from Gibco Invitrogen (Waltham,
MA, USA). XF Cell Mitostress kit was from Seahorse Bio-
science (North Billerica, MA, USA). Testosterone was from
AppliChem (Darmstadt, Germany). Horse serum (HS) was
from Amimed, Bioconcept (Allschwil, Switzerland).
Cell culture
In the present study, human neuroblastoma SH-SY5Y cells
stably expressing vector alone (pCEP4, control cells:
Mock) or the entire coding region of human wild-type APP
(APP695, APP cells) were used as described previously
[30]. Stably transfected cell clones were selected with
hygromycin. Cell cultures were kept under steady selection
pressure and checked on a routine basis for APP expression
levels [26]. APP cells secreted Ab levels in the pg/mL
range (around 150 pg/mL Ab1-40 compared to approxi-
mately 50 pg/mL secreted by vector control cells) [26, 31].
In addition, human SH-SY5Y neuroblastoma cells stably
transfected with wild-type (wtTau cells) and P301L mutant
tau (P301L cells) were used [32]. SH-SY5Y cells, either
harboring expression constructs encoding the longest
4-repeat isoform of human tau (wtTau) or tau with the
pathogenic FTDP-17 mutation P301L (P301L), showed
similar tau expression levels [27, 32], but the presence of
the P301L mutation is required for abnormal tau hyper-
phosphorylation and filament formation [32]. Cells were
kept under steady selection pressure with G418 (125 lg/
ml) and screened on a regular basis by routine histo-
chemical and biochemical assays.
Cells were grown at 37 C in a humidified incubator
chamber under an atmosphere of 7.5 % CO2 in DMEM
supplemented with 10 % (v/v) heat-inactivated FCS, 5 %
(v/v) heat-inactivated HS, 2 mM Glutamax, and 1 % (v/v)
penicillin/streptomycin. Cells were passaged 1–2 times per
week (the maximum number of passages after taking the
cells into culture did not exceed 15) and plated for treat-
ment when they reached 80–90 % confluence.
In experiments using differentiated cells, 96-well plates
were coated with 0.05 mg/ml collagen. Mock and APP
cells were plated at a density of 5 9 104 cells/well, and
wtTau and P301L cells were plated at a density of 1 9 104
cells/well. Cells were grown in Neurobasal medium sup-
plemented with 2 % B27, 2 mM Glutamax, and 1 % (v/v)
penicillin/streptomycin. Cells were treated for 5 days with
10 lM of retinoic acid and 50 ng/ml of BDNF (brain-
derived neurotrophic factor) before the treatment with
steroids started.
Treatment paradigm
Assessment of cell viability was performed on SH-SY5Y
neuroblastoma cells (Mock, APP, wtTau and P301L cells)
to determine the potential toxic concentration range of
neurosteroids (from 10 to 1000 nM, data not shown) using
an MTT reduction assay (Roche, Basel, Switzerland). On
the basis of the MTT results, and according to previous
data obtained in untransfected SH-SY5Y neuroblastoma
cells [19], a concentration of 100 nM was then selected and
used in all assays. Cells were treated 1 day after plating for
24 h either with DMEM (untreated control condition) or
with a final concentration of 100 nM progesterone, 17b-
estradiol, estrone, testosterone, or 3a-androstanediol made
from a stock solution in DMSO (final concentration of
DMSO\0.002 %, no effect of the vehicle solution
(DMSO) alone compared to the untreated condition). To
limit cell growth and to force the cells to function in an
aerobic state (high oxidative phosphorylation), the treat-
ment medium contained only a low amount of fetal calf
serum (5 % FCS) as well as glucose (1 g/l) and was sup-
plemented with 4 mM pyruvate.
For the stress experiments, cells were first pre-treated for
24 h with progesterone, estradiol, and testosterone and then
treated for 3 h with H2O2 (250 lM for APP cells and
500 lM for Mock and P301L cell). Then ATP assays were
performed and repeated at least 3 times.
ATP levels
Total ATP content was determined using a biolumines-
cence assay (ViaLighTM HT; Cambrex Bio Science)
according to the instructions of the manufacturer, as pre-
viously described [26]. Cells were plated in 5 replicates
Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by… 203
123
into a white 96-well cell culture plate at a density of
1.5 9 104 cells/well. The bioluminescent method measures
the formation of light from ATP and luciferin by luciferase.
The emitted light was linearly related to the ATP con-
centration and was measured using multilabel plate reader
VictorX5 (Perkin Elmer).
Determination of mitochondrial membrane
potential
The MMP was measured using the fluorescent dye
tetramethylrhodamine, methyl ester, perchlorate (TMRM)
[19]. Cells were plated in 6 replicates into a black 96-well
cell culture plate at a density of 1.5 9 104 cells/well. Cells
were loaded with the dye at a concentration of 0.4 lM for
15 min. After washing twice with HBSS, the fluorescence
was detected using the multilabel plate reader VictorX5
(PerkinElmer) at 531 nm (excitation)/595 nm (emission).
Transmembrane distribution of the dye is dependent on
MMP.
Mitochondrial respiration
The investigation of mitochondrial respiration and cellular
glycolysis was performed using the Seahorse Bioscience
XF24 analyser. XF24 cell culture microplates were coated
with 0.1 % gelatin and cells were plated at a density of
2.5 9 104 cells/well in 100 ll treatment medium contain-
ing 5 % FCS, 1 g/l glucose, and 4 mM pyruvate. After
neurosteroid treatment, cells were washed with 1X pre-
warmed PBS and 500 ll of DMEM containing 1 g/l of
glucose and 4 mM of pyruvate were added in each well.
The oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR) were recorded simultaneously
before and after the sequential injection of (1) oligomycin
(0.5 lM), (2) FCCP (2 lM), and (3) antimycin A and
rotenone (0.5 lM and 1 lM respectively). Data were
extracted from the Seahorse XF-24 software, and bioen-
ergetic parameters (basal respiration, ATP turnover,
maximal respiration, spare respiratory capacity, and gly-
colytic reserve) were calculated according to the guideline
of the company.
Statistical analysis
Data are given as the mean ± S.E.M. Statistical analyses
were performed using Graph Pad Prism software (version
5.02 for Windows, San Diego, California, USA). For sta-
tistical comparisons of more than two groups, one-way
ANOVA was used, followed by a Dunnett’s multiple
comparison tests versus the control. For statistical com-
parisons of two groups, student unpaired t tests were used.
P values\0.05 were considered statistically significant.
Results
APP and hyperphosphorylated tau differentially
impair mitochondrial bioenergetics
To measure the efficiency of mitochondrial respiration and
cellular bioenergetics in APP/Ab overexpressing cells, we
simultaneously monitored in real time the oxygen con-
sumption rate (OCR) (Fig. 1a), an indicator of
mitochondrial respiration, as well as the extracellular
acidification rate (ECAR) (Fig. 1b), an indicator of gly-
colysis, using a Seahorse Bioscience XF24 Analyzer. We
first performed experiments on untreated control and APP
cells to record AD-related differences in OCR and ECAR
readouts. A significant decrease (about 50 %) in basal
respiration, ATP turnover, maximal respiration, as well as
glycolytic reserve was observed in APP cells when com-
pared to control cells (Fig. 1c), paralleled by a reduction in
ATP levels (-20 % compared to control cells) (Fig. 1d).
Surprisingly, a slight increase in MMP was observed in
APP cells (Fig. 1e), translating to a hyperpolarization of
the mitochondrial membrane potential.
The same experiments were conducted to characterize
wtTau and P301L cells (Fig. 2). No significant difference
in basal respiration, ATP turnover, and glycolytic reserve
was found between the two cell lines (Fig. 2a–c). However,
wtTau cells had higher maximal respiration and spare
respiratory capacity than P301L-transfected cells, indicat-
ing that mutant cells have some level of metabolic
impairment, especially with regard to their mitochondrial
reserve capacity (Fig. 2c). ATP levels were also signifi-
cantly reduced in P301L cells (-27 % compared to wtTau
cells) (Fig. 2d), which was paralleled by a depolarization
of the mitochondrial membrane potential (decreased MMP,
-10 % compared to wtTau cells) (Fig. 2e).
Taken together, these results confirm that APP/Ab and
hyperphosphorylated tau exhibit a negative impact on
mitochondrial function leading to mitochondrial respiration
deficiency and diminished ATP outcome. Since different
bioenergetic parameters are impaired between APP and
P301L cells, Ab and abnormal tau appear to exert a dif-
ferent degree of toxicity on mitochondrial function.
Sex steroid hormones distinctively increase
mitochondrial bioenergetics in APP/Ab and tau-
overexpressing cells
To determine whether treatment with neurosteroids can
improve mitochondrial function in AD cell culture models,
ATP levels and MMP were analyzed in APP/Ab and tau-
overexpressing cells after 24 h of treatment (concentration
100 nM) with a range of steroids: progesterone (P),
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estradiol (E2), estrone (E1), testosterone (T), and 3a-an-
drostanediol (3a) (Fig. 3). In undifferentiated APP cells, all
steroids tested by us were able to significantly increase
ATP levels as well as MMP (Fig. 3a, b), while in the dif-
ferentiated state of APP cells only the male sex hormone
testosterone was effective (Suppl. Figure 1). In contrast, in
P301L cells, the female sex hormones progesterone and
estradiol induced a significant increase in ATP levels in the
undifferentiated (Fig. 3c) as well as differentiated state
(Suppl. Figure 1). Progesterone was particularly effective
since ATP levels in P301L cells were even higher (?6 %)
compared to those of the untreated wtTau cells. In addition,
all the tested steroids, except for testosterone, significantly
increased MMP in P301L cells (Fig. 3d), with estrogens
(E2 and E1) having the highest effect (?8 % compared to
untreated P301L cells). To characterize the bioenergetic
modulating profile of sex steroids on APP/Ab and tau-
overexpressing cells, measurements with a Seahorse Bio-
science XF24 analyzer were performed after 24 h of
treatments (at a 100 nM concentration) (Figs. 4, 5). In
APP/Ab overexpressing cells, only the testosterone treated
group exhibited a higher basal respiration (Fig. 4a), ATP
turnover (Fig. 4b), maximal respiration (Fig. 4c), spare
respiratory capacity (Fig. 4d), and glycolytic reserve
(Fig. 4e) compared to the untreated control group. In
addition, 3a-androstanediol induced an improvement in the
spare respiratory capacity (Fig. 4d) and progesterone sig-
nificantly increased glycolytic reserve (Fig. 4e). These data
suggest that especially testosterone, the main male sex
hormone, exhibits a beneficial impact on mitochondrial
malfunction in AD cells that are modeling the Ab
pathology.
Regarding the bioenergetic modulating profile of sex
steroids on P301L cells, no significant changes were pre-
sent in basal respiration (Fig. 5a). Nevertheless, the two
main female sex hormones, progesterone and estradiol,
significantly enhanced ATP turnover (Fig. 5b), maximal
respiration (Fig. 5c), as well as spare respiratory capacity
(Fig. 5d) compared to the untreated P301L cells. Estrone
(E1), another estrogen, was also able to significantly
increase spare respiratory capacity (Fig. 5d), and 3a-an-
drostanediol was the only steroid able to grow the
glycolytic reserve in P301L cells (Fig. 5e). Together, these
data suggest that mainly female sex steroid hormones,
progesterone and estradiol/estrone, improve mitochondrial
bioenergetics in cells modeling tau pathology.
Fig. 1 Characterization of bioenergetic deficits in APP cells. a Oxy-
gen consumption rate (OCR) and b extracellular acidification rate
(ECAR) of Mock and APP cells were simultaneously measured using
a XF24 Analyzer (Seahorse Bioscience). The sequential injection of
mitochondrial inhibitors is indicated by arrows (see details in the
‘‘Materials and methods’’ section). Changes in the OCR and ECAR
are shown as a percent change from baseline (=100 %, dashed line).
c Values corresponding to the different bioenergetic parameters are
represented as mean ± SEM (n = 8–10 replicates). d ATP levels and
e mitochondrial membrane potential (MMP) in Mock and APP cells.
Values represent the mean ± SEM (n = 12–18 replicates of three
independent experiments). Student unpaired t test, *P\ 0.05;
***P\ 0.001. O oligomycin, F FCCP, R/A rotenone/antimycin A
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A full analysis of preference for oxidative phosphory-
lation as indicated by percent of OCR dedicated to ATP
turnover (Fig. 6a, c) or spare respiratory capacity (Fig. 6b,
d) versus the use of glycolytic reserves was performed in
both APP/Ab and tau-overexpressing cells. A tendency for
higher or lower metabolic activity is displayed on a second
axis. Overall, APP cells were switched to a metabolically
more active state after treatment with androgenic com-
pounds (testosterone and 3a-androstanediol), with a
tendency to increase both glycolytic reserve (ECAR) and
ATP turnover/spare respiratory capacity (OCR) (Fig. 6a–
b). In P301L cells, ATP turnover and spare respiratory
capacity were enhanced by progesterone and estrogenic
compounds (estradiol and estrone), leading to a more aer-
obic state (Fig. 6c–d).
Taken together, these results indicate that distinct sex
steroid hormones are able to improve mitochondrial
bioenergetics in APP/Ab and tau-overexpressing cells by
increasing ATP levels, MMP, and mitochondrial respira-
tion which contribute to the alleviation of mitochondrial
deficits observed in those cell lines. In this regard, the main
players in the group seem to be progesterone, estradiol
(E2), and testosterone.
Protective effects of neurosteroids against the oxidative
stress-induced drop of ATP levels.
Since enhanced and unopposed metabolism-driven
oxidative stress has a major role in age-related diseases
including AD, we further wanted to assess whether sex
hormone-related neurosteroids also exert a protective effect
against oxidative stress. Therefore, we investigated ATP
levels in APP/Ab- and mutant tau-overexpressing cells
after a 24 h pre-treatment with progesterone, estradiol, and
testosterone followed by a 3 h treatment with hydrogen
peroxide (H2O2). Because the two cell lines express dif-
ferent thresholds for vulnerability to oxidative stress, we
used the respective concentration of H2O2 that induced a
slight drop of about 10–15 % in ATP levels, namely
250 lM for APP cells and 500 lM for P301L cells (data
not shown).
Similar to the unstressed situation, all three neuros-
teroids were able to significantly attenuate the H2O2-
induced drop in ATP levels in APP cells (Fig. 7a), while
progesterone and estradiol were again selectively effective
in P301L cells (Fig. 7b).
Together, these results indicate that sex steroid hor-
mones may exert a distinct protective effect in APP/Ab and
Fig. 2 Characterization of bioenergetic deficits in P301L cells.
a Oxygen consumption rate (OCR) and b extracellular acidification
rate (ECAR) of wtTau and P301L cells were simultaneously
measured using a XF24 Analyzer (Seahorse Bioscience). The
sequential injection of mitochondrial inhibitors is indicated by arrows
(see details in the ‘‘Materials and methods’’ section). Changes in the
OCR and ECAR are shown as a percent change from baseline
(=100 %, dashed line). c Values corresponding to the different
bioenergetic parameters are represented as mean ± SEM (n = 8–10
replicates). d ATP levels and e mitochondrial membrane potential
(MMP) in wtTau and P301L cells. Values represent the mean ± SEM
(n = 12–18 replicates of three independent experiments). Student
unpaired t test, *P\ 0.05; ***P\ 0.001. O oligomycin, F FCCP, R/
A rotenone/antimycin A
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Fig. 3 Neurosteroids increase ATP level and MMP in APP and
P301L cells. ATP levels and MMP were measured after neurosteroid
treatment for 24 h at a concentration of 100 nM in APP cells (a–
b) and P301L cells (c–d), respectively. Values represent the
mean ± SEM (n = 12–18 replicates of three independent experi-
ments) and were normalized to 100 % of untreated Mock cells (a–
b) or untreated wtTau cells (c–d). The values for untreated APP (a–
b) and P301L cells (c–d) were also indicated by a dashed line. One-
way ANOVA and post hoc Dunnett’s multiple comparison test versus
untreated Mock or wtTau, *P\ 0.05; **P\ 0.01; ***P\ 0.001.
P progesterone, E2 estradiol, E1 estrone, T testosterone, 3a 3a-
androstanediol
Fig. 4 Effects of neurosteroids
on bioenergetic parameters in
APP cells. a Basal respiration,
b ATP turnover, c maximal
respiration, d spare respiratory
capacity, and e glycolytic
reserve were measured after
neurosteroid treatment for 24 h
at a concentration of 100 nM in
APP cells, using a XF24
Analyzer (Seahorse
Bioscience). Values represent
the mean ± SEM (n = 8–10
replicates) and were normalized
to 100 % of the control group
(untreated APP cells, dashed
line). One-way ANOVA and
post hoc Dunnett’s multiple
comparison test versus control,
*P\ 0.05; ***P\ 0.001.
P progesterone, E2 estradiol, E1
estrone, T testosterone, 3a 3a-
androstanediol
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Fig. 5 Effects of neurosteroids
on bioenergetic parameters in
P301L cells. a Basal respiration,
b ATP turnover, c maximal
respiration, d spare respiratory
capacity, and e glycolytic
reserve were measured after
neurosteroid treatment for 24 h
at a concentration of 100 nM in
P301L cells, using a XF24
Analyzer (Seahorse
Bioscience). Values represent
the mean ± SEM (n = 8–10
replicates) and were normalized
to 100 % of the control group
(untreated P301L cells, dashed
line). One-way ANOVA and
post hoc Dunnett’s multiple
comparison test versus control,
*P\ 0.05; ***P\ 0.001.
P progesterone, E2 estradiol, E1
estrone, T testosterone, 3a 3a-
androstanediol
Fig. 6 Neurosteroids differentially regulate the bioenergetic profile
in APP/Ab and abnormal tau-overexpressing cells. a–b Characteriza-
tion of bioenergetic profiles of APP cells after neurosteroid treatment
along two axes. Degree of a ATP turnover or b spare respiratory
capacity is shown (in ordinate) in function of glycolytic reserve (in
abscissa). The same parameters are displayed for P301L cells (c–d),
respectively. Values represent the mean of each group normalized to
the control group (untreated APP or P301L cells = 100 %). Signif-
icant changes upon respiratory parameters are highlighted by dashed
circles. P progesterone, E2 estradiol, E1 estrone, T testosterone, 3a
3a-androstanediol, aero. aerobic, metab. metabolic, glyco. glycolytic
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mutant tau-overexpressing cells by increasing ATP levels
when cells are exposed to oxidative stress condition.
Discussion
In this study, we distinguished the effects of several neu-
rosteroids on ATP synthesis, the MMP, mitochondrial
respiration, and glycolysis in two cellular AD models. Our
key findings were that (1) APP/Ab and mutant tau-overex-
pressing cells present distinct bioenergetic impairments,
with APP/Ab having the strongest deleterious effect on
mitochondrial function and (2) the male steroid hormone,
testosterone, was more efficient in alleviating mitochondrial
deficits in a model of AD-related amyloidopathy, whereas
the female steroid hormones, progesterone and estrogen,
were more efficient in increasing bioenergetic outcomes in a
model of AD-related tauopathies. In addition, this protective
pattern was evident under physiological as well as oxidative
stress conditions.
Remarkably, bioenergetic profiles were differentially
impacted in APP/Ab-overexpressing cells and abnormally
hyperphosphorylated tau-overexpressing cells. Only the
maximal respiration and spare respiratory capacity were
reduced in P301L cells, while APP cells presented, in
addition, a decrease in basal respiration, ATP turnover, and
glycolytic reserve. A drop in ATP levels was observed in
both cell lines as well as a decreased MMP in P301L cells.
Interestingly, APP cells presented with a slightly hyper-
polarized mitochondrial membrane compared to the Mock
control cells. This characteristic was previously observed
in PC12 cells overexpressing APP bearing the Swedish
mutation (APPsw), another cellular model mimicking Ab
pathology [33]. The authors hypothesized that this hyper-
polarization may be due to increased nitric oxide levels
present in this cell line when Ab production is enhanced.
Of note, Ab secretion was similar in the wild-type APP-
overexpressing human SH-SY5Y cells used in the present
study and in APPsw-overexpressing PC12 cells within the
low nanomolar range [31, 33], whereas higher Ab levels
obviously lead to MMP depolarization [33].
The different bioenergetic output observed between
APP/Ab and abnormal tau-overexpressing cells can be
explained by the fact that Ab and tau target mitochondria
differentially [34]. Indeed, previous data from our group
had shown that APP cells present a decreased mitochon-
drial complex IV activity [26], whereas complex I activity
was impacted in P301L cells [27]. In line with, these
findings are previous data from our group showing that a
treatment of native SH-SY5Y cells with Ab peptide
decreased complex IV activity, which was coupled to a
decrease in the respiratory control ratio [35]. Notably,
deregulation of complex IV activity, and content, was
previously observed in platelets, in fibroblasts, and in the
brain of SAD patients already at early stages of the disease
[8]. Moreover, we had shown that the Ab peptide and
abnormally hyperphosphorylated tau protein may act syn-
ergistically to trigger mitochondrial dysfunction in a triple
transgenic mouse model of AD (tripleAD) obtained after
crossing P301L tau transgenic mice with APPswPS2 dou-
ble-transgenic mice [36]. The investigation of oxidative
phosphorylation (OXPHOS) activity had revealed that
deregulation of complex I activity was related to tau,
whereas deregulation of complex IV activity was depen-
dent on Ab.
Thus, on the one hand, the lower complex I activity
observed in P301L cells may lead to a decreased ability to
reach maximal respiration, which reduces the spare respi-
ratory capacity of the cells. On the other hand, the reduced
complex IV activity, which is directly involved in oxygen
consumption, may decrease additional respiratory param-
eters, including ATP turnover in APP cells.
Whether mitochondrial deficits are the causes or conse-
quences of Ab accumulation and tau hyperphosphorylation
is still under debate. Recent reports indicate that mitochon-
drial dysfunction may represent the missing link between
normal aging and SAD. As a genetic disorder, FAD clearly is
a consequence of malfunctioning/mutated genes, while late-
onset sporadic AD is more likely due to a gradual accumu-
lation of age-related malfunction. Normal aging and AD are
both marked by defects in brain metabolism and increased
oxidative stress, albeit to varying degrees. Mitochondria are
involved in these two phenomena by controlling cellular
bioenergetics and redox homeostasis. Consequently,
Swerdlow and colleagues placed mitochondria in the center
Fig. 7 Neurosteroids are protective against the H2O2-induced drop
of ATP levels in APP and P301L cells. a APP cells and b P301L cells
were pre-treated 24 h with progesterone (P), estradiol (E2), and
testosterone (T) and then stressed with a 250 lM H2O2 (APP cells) or
b 500 lM H2O2 (P301L cells). Values represent the mean ± SEM
(n = 12–18 replicates of three independent experiments) and were
normalized to 100 % of APP cells (a) and P301L cells (b) not pre-
treated with our selection of neurosteroids (Ctr control). One-way
ANOVA and post hoc Dunnett’s multiple comparison test versus
control APP or P301L, *P\ 0.05; **P\ 0.01; ***P\ 0.001
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of neurodegenerative processes in the ‘‘Alzheimer mito-
chondrial cascade hypothesis’’ [15]. This hypothesis
postulates that the decline of mitochondrial function
observed during aging, namely the decrease in energy pro-
duction and the increase in ROS production and oxidative
stress, eventually surpasses a threshold, thereby giving rise to
the amyloidogenic pathway leading to Ab accumulation.
This triggers a vicious cycle in which Ab may exacerbate
mitochondrial deficits, creating other vicious cycles that also
involve tau hyperphosphorylation, and eventually lead to
neurodegeneration and dementia [37, 38]. Thus, there exists
a very complex, and yet not well understood, interaction
between the mainly age-related early onset of mitochondrial
deficits, Ab accumulation, and tau hyperphosphorylation,
emphasizing that interventions targeting mitochondrial
deficits may serve as potential strategies for the prevention or
treatment of age-related neurodegenerative disorders.
In our study, the treatment with sex steroid hormones
was able to alleviate the bioenergetic impairments observed
in APP and P301L cells in general. More specifically, the
male hormone testosterone was able to enhance all the
bioenergetic parameters that were impaired in APP/Ab
overexpressing cells, namely basal respiration, ATP turn-
over, maximal respiration, and cellular glycolysis as well as
ATP levels specifically in differentiated APP cells, indi-
cating that cell sensitivity towards this hormone may
increase during differentiation. In contrast, treatment with
female hormones improved maximal respiration and spare
respiratory capacity, two bioenergetic parameters that were
disturbed in P301L cells. ATP turnover is an indication of
the coupling efficiency that is directly linked to ATP pro-
duction in mitochondria. Bioenergetic profiling revealed
that male and female steroid hormones were able to dif-
ferentially increase ATP synthesis in APP and P301L cells,
respectively. The spare respiratory capacity and glycolytic
reserve provide an indication of the ability of a cell to
respond to stress under conditions of increased energy
demand [39]. The spare respiratory capacity was increased
by estrogens and progesterone in P301L cells, whereas both
parameters were enhanced after treatment with androgen in
APP cells. Together, the data indicated that the cells were
switched to a metabolically more active state, with a ten-
dency to increase both ATP synthesis and metabolic
reserves. In addition, male and female sex hormones were
able to increase ATP levels after oxidative injury in APP
cells, when only progesterone and estradiol showed a sig-
nificant effect on this bioenergetic parameter in P301L
cells. These data suggest that the neurosteroids belonging to
the sex hormone family may not only exert neuroprotective
effects against Ab- or tau-related toxicity but also against
oxidative stress, a key feature of brain aging.
The ability of neurosteroids to modulate cellular
bioenergetics and redox homeostasis was the focus of a
recent study by our group. In particular, we showed that
neurosteroids, including the steroids that were investigated
in the present study, were able to increase ATP levels and
mitochondrial respiration in native SH-SY5Y neuroblas-
toma cells and mouse cortical neurons [19]. In parallel,
they modulated redox homeostasis by increasing antioxi-
dant activity, probably as a compensatory response to
oxidative stress due to a slight enhancement in reactive
oxygen species (ROS) levels resulting from the neuros-
teroid-induced boost in oxygen consumption [19].
Moreover, we showed that the effects we observed were, at
least in part, mediated by steroid (progesterone, estrogen,
and androgen) receptor activation since the inhibition of
those receptors by specific antagonists shut down the
effects of the corresponding steroid ligand on ATP
production.
Steroid receptors are nuclear receptors involved in the
regulation of gene expression. With regard to bioenerget-
ics, estrogens have been shown to up-regulate genes
encoding some of the electron transport chain components
such as not only subunits of mitochondrial complex I (CI),
cytochrome c oxidase (complex IV), and the F1 subunit of
ATP synthase but also glucose transporter subunits,
enzymes involved in the tricarboxylic acid cycle (TCA
cycle) and glycolysis, leading to increased glucose uti-
lization and mitochondrial respiration (reviewed in [18]).
Of note, since the mitochondrial genome itself contains
hormone responsive elements, it has been proposed that
estradiol and testosterone can regulate energy production
by inducing mitochondrial oxidative phosphorylation
(OXPHOS) genes encoded in the mitochondrial DNA [40].
In a similar way, progesterone has been shown to increase
complex IV and V (ATP synthase) expression, accompa-
nied by enhanced mitochondrial respiratory activity [41].
With regard to the results obtained in the present study, we
can speculate that the underlying mechanisms are similar
and that the effects we observed are, at least in part,
mediated by an increased expression of genes involved in
OXPHOS and glycolysis. Further investigations will be
needed to identify in detail which genes are concerned.
It is interesting to observe that sex steroid hormones
present distinct mitochondrial improvements with regard to
their bioenergetic profiles in the presence of Ab-related or
tau-related mitochondrial dysfunction. Estrogens and pro-
gesterone seem to confer beneficial effects on
mitochondrial-related dysfunction preferentially in tau
pathology, whereas testosterone was more efficient in
alleviating mitochondrial deficits in APP/Ab overexpress-
ing cells. These findings may imply that women and men
differentially respond to mitochondrial insults mediated by
either Ab or abnormal tau.
Epidemiological studies report a higher prevalence and
incidence of AD in women even as well as a greater
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vulnerability to the disease, since they represent two thirds
of SAD patients [42, 43]. In particular, AD pathology is
more strongly associated with clinical dementia in female
patients than in male [44]. Besides, women exhibit greater
senile plaque deposition than men already at early stages of
neurofibrillary tangle development [45] and show a higher
vulnerability to oxidative damage [46]. These observations
are also made in transgenic animal models. Indeed, in
simple (Tg2576) [47], double (APP/PS1) [48], as well as in
triple (3xTg-AD) transgenic mice [49], an increased Ab
load burden and plaque number was found in the female
brain compared to age-matched male mouse brain. These
differences were even more striking in old females after the
age of 11 months when the estrous cycle became irregular
or when animals were ovariectomized (OVX). In these
females, a significant enhancement of Ab load in important
brain regions like the hippocampus was observed [49, 50].
In addition, in female 3xTgAD mice, mitochondrial
bioenergetic deficits and oxidative stress, which occur
before the onset of AD pathology, were exacerbated in
OVX females compared to sham OVX animals [50, 51]. A
treatment with female sex hormones (estradiol or proges-
terone) was able to reduce Ab load and NFT formation and
also rescue mitochondrial deficits in OVX 3xTgAD mice
[50, 52]. Interestingly, in a study using demasculinized
3xTgAD males, these animals exhibited a significant
increase in brain Ab load compared to normal males, while
in defeminized female mice, Ab accumulation was com-
parable to that of males in some brain regions [49].
Taken together, these findings highlight the important
role of sex hormones in the development of AD in both
male and females.
Indeed, the sudden drop in estrogen levels in women
after menopause has been proposed to be one risk factor in
AD. Indeed, estradiol is the major product of estrogen
biosynthesis, and it remains the most abundant estrogen in
a woman’s pre-menopausal life. After menopause, women
have estradiol levels comparable to men, and it is then that
women become more susceptible to AD. Thus, the pre-
cipitous decline of estrogens during menopause may
contribute to AD onset as well as a greater vulnerability to
the disease in women [18]. Men, in contrast, present with a
gradual reduction in testosterone over the life course
eliminating approximately 2 % of circulating testosterone
every year [53]. Interestingly, human and animal studies
also suggest that androgen deprivation represents a risk
factor for AD pathogenesis [54–56]. Notably, in a triple
transgenic mouse model of AD (3xTgAD), it has been
shown that orchiectomized males presented with increased
Ab accumulation in the brain, coupled with impaired
cognitive performances compared to sham-operated mice
[57]. Treatment with androgens significantly attenuated the
increase in AD pathology [55, 57]. Further studies have
indicated that advancing age in men enhances tau hyper-
phosphorylation consistent with AD pathology [58]. These
findings suggest that the influence of steroids on tau
remains a promising, yet underexplored research avenue in
AD. Of note, no sex predilection has been identified in
patients with FTDP-17, a disease characterized by a strictly
tau-dependent pathology [59, 60]. However, in a study
using mice bearing the P301S tau mutation, a greater tau
accumulation was evident in different brain region of males
already at an age of 7 months, as well as a more apparent
mitochondria proteome deregulation in male P301S mito-
chondria [61].
Together, these findings suggest that the relationship
between hormonal loss and the risk to develop AD may be
preferentially linked to Ab pathology in females and tau
pathology in males.
A few studies have focused on the impact of steroids on
abnormal tau. Liu and colleagues discovered that protein
kinase A may initiate phosphorylation of tau, and estradiol
treatment of human embryonic kidney cells attenuated
protein kinase A activity as well as reduced tau phospho-
rylation [62]. Estradiol also exhibited a rescue of aberrant
tau in primary rat cortical neurons and SH-SY5Y neurob-
lastoma cells [63]. Additional studies showed that both
estrogen and progesterone were able to modulate activities
of kinases and phosphatases involved in the regulation of
tau phosphorylation, possibly by modulating the glycogen
synthase kinase (GSK) pathway [54]. Specifically, estrogen
appeared to reduce GSK-3b activity while progesterone
decreased the expression of both GSK-3b and tau [54, 63].
Regarding AD-linked Ab pathology, studies have focused
on the impact of estrogen on the deposition and clearance
of Ab [64, 65]. Both estrone and estradiol decreased
polymerization and stabilization of Ab [65, 66]. Other
studies indicate that deficiencies in estrogen-related ster-
oids can exacerbate Ab plaques in AD mouse models and
that treatment with estradiol was able to reduce Ab burden,
possibly via stimulating the non-amyloidogenic pathway of
APP processing [64, 67]. The effects of progesterone on
Ab deposition and clearance are less investigated, but a
recent study showed that progesterone and estradiol
encouraged an increase in the expression of Ab clearance
factors both in vitro and in vivo [68].
In the present study, testosterone was shown to ame-
liorate the effects of mitochondrial dysfunction caused by
APP/Ab but not abnormal tau. In our previous study
investigating neurosteroid effects on bioenergetics under
physiological conditions, the testosterone metabolite, 3a-
androstanediol, presented an effect similar to its precursor
and was able to increase MMP, ATP levels, and mito-
chondrial respiration in untransfected neuroblastoma cells
and primary cortical cells [19]. Here, 3a-androstanediol
was less efficient in alleviating bioenergetic deficits in APP
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cells, suggesting a distinct mode of action compared to
testosterone. Neuroprotective effects of testosterone on
hyperphosphorylated tau are less well characterized in the
literature. Testosterone appears to prevent tau hyperphos-
phorylation in an in vivo model of heat shock induced
phosphorylation through inhibition of GSK-3b signaling
[58]. Interestingly, Rosario and colleagues [56] revealed
reduced abnormal tau accumulation in gonadectomized
male 3xTgAD mice treated with testosterone or estradiol
but not the testosterone metabolite dihydrotestosterone
(DHT). This implies that testosterone may exert indirect
effects on tau hyperphosphorylation via its conversion to
estradiol by the enzyme aromatase and by acting on
estrogen receptors. In the same model, testosterone and
DHT were able to decrease Ab deposits with a higher
efficiency than estradiol, suggesting an androgen receptor-
dependent mechanism. Overk and colleagues (2013) [69]
examined basal levels of serum and brain testosterone in
male 3xTgAD mice and found that testosterone levels rise
with disease progression. This increase in testosterone in
aged male 3xTgAD mice was correlated with a reduced Ab
plaque pathology. This suggests that testosterone may have
some neuroprotective benefits on the AD disease course,
but that testosterone administration is associated more with
a lower Ab protein burden rather than abnormal tau pro-
tein. In fact, testosterone has been shown to alter
processing of amyloid precursor protein and enhances
expression of neprilysin, an Ab-degrading enzyme [70].
The decrease in sex steroid hormones was proposed to be
one risk factor of AD in both men and women. However,
there is little information concerning changes of steroid
levels in the human brain during aging and under dementia
conditions. Steroid hormones originating from the endocrine
glands can freely pass through the blood–brain barrier and
act on nervous tissues. Since steroids can also be synthesized
within the nervous system, changes in blood levels of ster-
oids with increasing age do not necessarily reflect changes in
brain levels. Schumacher and colleagues quantified levels of
different neurosteroids in various brain regions of aged AD
patients and aged non-demented controls [24]. They showed
a general trend towards lower neurosteroid levels in AD
patients. Additionally, neurosteroid levels were negatively
correlated with Ab and abnormal tau in some brain regions,
suggesting a link between neurosteroid homeostasis and AD
pathogenesis. However, large studies investigating system-
atically gender differences with respect to Ab and/or tau
pathology in post-mortem brains from AD patients are still
missing. Since the two hallmarks are present in AD brains
and are both involved in the pathophysiology of the disease, a
strict dichotomy between Ab- and tau-related deficit in
females and males, respectively, is not easy and requires a
more thoughtful investigation. In addition, one needs to
consider that, even if the brain and the peripheral levels of
steroids are not directly correlated in all cases, circulating
sex hormones contribute to the brain pool of steroids, due to
their ability to cross the blood–brain barrier. Indeed, evi-
dence is provided that a decrease in circulating steroid
hormones, during aging or after ovar-/gonadectomy, is
accompanied by a decrease in brain levels of these steroids
[55, 71, 72]. In this context, different concepts of hormonal
replacement therapies for women and men are currently
discussed with regard to the use of estradiol and testosterone,
respectively, to assess the effect of sex hormones in
decreasing the risk of dementia, including AD [73, 74].
Longitudinal proof-of-concept studies are now needed to
identify an optimal window of opportunity to optimize
treatment efficacy as well as safety.
Our experiments revealed a rescue of metabolic dys-
function in models of AD-linked tauopathies and
amyloidopathies with neurosteroids belonging to the sex
hormone family. Taking into account the data available in
the literature and in our previous study, this rescue may
possibly occur at two levels: (1) neurosteroids may directly
boost mitochondrial function via gene regulation and (2)
neurosteroids may decrease Ab accumulation and NFT
formation, thereby alleviating mitochondrial impairments
induced by Ab and tau. An interaction between these
mechanisms cannot be excluded.
Given the complex interaction that seems to link mito-
chondrial function, gender, and the pathophysiology of
AD, our findings have shown that sex steroid hormones
may represent interesting therapeutic tools to counteract
bioenergetic deficits in AD. Thus, experiments dissecting
the mechanistic pathways of neurosteroid function under-
lying the gender differences in AD are interesting research
paths for the better understanding of how neurosteroids
impact mitochondrial function in AD. Ultimately, our
research will potentially open new avenues for the devel-
opment of gender-specific therapeutic strategies in AD.
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